<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113538</url>
  </required_header>
  <id_info>
    <org_study_id>GOGIUNTA</org_study_id>
    <nct_id>NCT04113538</nct_id>
  </id_info>
  <brief_title>Treat and Extend Analysis Trial With Aflibercept in Wet-AMD</brief_title>
  <official_title>Exploratory and Descriptive Study Evaluating the Efficacy of Aflibercept in Bimonthly Injections Versus the ''Treat and Extend'' Dosing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michel Giunta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GOGiunta</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, prospective, exploratory, descriptive, open label, parallel&#xD;
      group, post-authorization study designed to describe and evaluate two aflibercept treatment&#xD;
      regimens aimed at achieving and maintaining a maximum visual function benefit (i.e., BCVA&#xD;
      stability). The goal of the study is to compare two strategies for dosing regimen with&#xD;
      aflibercept in wet AMD: the standard regimen (one injection every 8 weeks after 3 monthly&#xD;
      loading doses in the treatment of wet age-related macular degeneration) versus the treat and&#xD;
      extend protocol (details outlined below in the &quot;Study Design&quot; section) aiming at achieving&#xD;
      and maintaining maximum visual acuity benefit while minimizing the number of injections.&#xD;
      Patients will be randomized at week 8 (Month 2) in a proportion of 1:2 (Standard treatment :&#xD;
      treat and extend treatment). We aim to demonstrate that the Treat and Extend regimen is&#xD;
      equivalent or better to the standard fixed interval regimen in terms of change in patients'&#xD;
      visual acuity after a year of treatment and that patients in the Treat and Extend arm will&#xD;
      receive fewer injections and fewer visits, than their counterparts in the standard regimen&#xD;
      arm. The results could be used to generate a base for future controlled-randomized clinical&#xD;
      trials on the timing of treatment administration for patients with wAMD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best Corrected Visual Acuity</measure>
    <time_frame>from baseline to week 52 (Month 12)</time_frame>
    <description>Change in BCVA as measured in with an ETDRS chart</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Injections</measure>
    <time_frame>from baseline to week 52 (Month 12)</time_frame>
    <description>Number of injections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Treatment-free intervals</measure>
    <time_frame>from baseline to week 52 (Month 12)</time_frame>
    <description>Treatment frequency and duration of treatment-free intervals applied in the treat and extend dosing regimen arm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gain of letters</measure>
    <time_frame>from baseline to week 52 (Month 12)</time_frame>
    <description>Proportion of patients with gain of 5 or more, 10 or more, and 15 or more letters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loss of letters</measure>
    <time_frame>from baseline to week 52 (Month 12)</time_frame>
    <description>Proportion of patients with loss of 5 or more, 10 or more, and 15 or more letters</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Wet Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed by an injection every 8 weeks until the end of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treat and Extend</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 ml (40 mg/ml) of Eylea solution : loading dose of 3 intravitreal injections every 4 weeks for the first 3 months followed and, until the end of the study, retreatment interval based on disease stability</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intraocular injection of 2 ml (40mg/ml)</description>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_label>Treat and Extend</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who are able to give written informed consent&#xD;
&#xD;
          -  Patients 50 years of age or older&#xD;
&#xD;
          -  Patients with a diagnosis of treatmenttreatment-naive CNV secondary to AMD in the&#xD;
             study eye, for which aflibercept treatment hashas been prescribed by the treating&#xD;
             physician. This includes patients with lesion(s) with less than 50% hemorrhage, less&#xD;
             that 50% fibrosis, and/or serious pigment epithelial detachment (PED)&#xD;
&#xD;
          -  Patients with best corrected visual acuity score in the study eye between 78 and 19&#xD;
             letters inclusively, using ETDRS visual acuity testing charts at a testing distance of&#xD;
             4 meters (approximate Snellen equivalent of 20/32 to 20/400 at screening)&#xD;
&#xD;
          -  Females of childbearing potential must, in the opinion of the Investigator, be using a&#xD;
             medically effective method of contraception to prevent pregnancy and agree to use an&#xD;
             acceptable method of contraception for the duration of their participation in this&#xD;
             study. Effective contraception should be used by subjects during the study and for&#xD;
             three months after treatment. Effective methods of contraception include, but are not&#xD;
             limited to, (i) condoms (male or female) with or without a spermicidal agent; (ii)&#xD;
             diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv)&#xD;
             hormone-based contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a structural foveal damage - advanced sub retinal fibrosis or&#xD;
             significant geographic atrophy involving the foveal center (lack of morphological&#xD;
             reserve) in the study eye&#xD;
&#xD;
          -  Patients with confounding severe ocular disease in the study eye (such as uncontrolled&#xD;
             glaucoma, diabetic retinopathy likely to be visually significant within 2 years,&#xD;
             cataract presumably requiring surgery within 2 years) -vitreous or pre-retinal&#xD;
             haemorrhage obscuring the central macula, or presence of rhegmatogenous retinal&#xD;
             detachment&#xD;
&#xD;
          -  Patients with clinical suspicion of polypoidal choroidal vasculopathy&#xD;
&#xD;
          -  Patients with active or suspected ocular per ocular infections in either eye&#xD;
&#xD;
          -  Patients with active intraocular inflammation in either eye&#xD;
&#xD;
          -  Patients with a known sensitivity to Aflibercept or any component of its formulation&#xD;
&#xD;
          -  Patients physically unable to tolerate intravenous fluorescein angiography&#xD;
&#xD;
          -  Pregnant or breastfeeding female patients&#xD;
&#xD;
          -  Any patient with recent history of new onset cardiac disease or thromboembolic event&#xD;
             (within 12 months of Baseline visit)&#xD;
&#xD;
          -  Patients having received systemic treatment with any other anti-VEGF therapy 60 days&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Patients having had any prior treatment in the study eye (Avastin, Lucentis, Visudyne,&#xD;
             Ozurdex, external radiation therapy, transpupillary thermotherapy, or any intravitreal&#xD;
             injection)&#xD;
&#xD;
          -  Concurrent participation in a clinical trial or within 30 days prior to enrollment&#xD;
&#xD;
          -  Patients with any other condition which, in the opinion of the principal investigator,&#xD;
             would require treatment that would significantly impact the treatment assessments&#xD;
             during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Veronique Noel</last_name>
    <phone>819-563-4558</phone>
    <phone_ext>105</phone_ext>
    <email>etude_administration@gogiunta.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annick Lavall√©e</last_name>
    <phone>819-563-4558</phone>
    <phone_ext>105</phone_ext>
    <email>annick.gogiunta@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GOGIUNTA</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1G 2V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Noel</last_name>
      <phone>1-819-563-6889</phone>
      <phone_ext>105</phone_ext>
      <email>etude_administration@gogiunta.com</email>
    </contact>
    <contact_backup>
      <last_name>Annick Lavallee</last_name>
      <phone>1-819-563-6889</phone>
      <phone_ext>105</phone_ext>
      <email>annick.gogiunta@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michel Giunta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>GOGiunta</investigator_affiliation>
    <investigator_full_name>Michel Giunta</investigator_full_name>
    <investigator_title>P.I.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

